Short Interest in Bavarian Nordic A/S (OTCMKTS:BVNRY) Increases By 39.6%

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 7,400 shares, an increase of 39.6% from the February 13th total of 5,300 shares. Currently, 0.0% of the company's stock are sold short. Based on an average daily trading volume, of 15,500 shares, the short-interest ratio is currently 0.5 days.

Bavarian Nordic A/S Stock Up 0.2 %

OTCMKTS:BVNRY traded up $0.02 during trading hours on Wednesday, hitting $8.09. 15,825 shares of the company traded hands, compared to its average volume of 10,844. The company has a market cap of $1.91 billion, a PE ratio of 11.72 and a beta of 1.83. The firm's 50-day simple moving average is $8.35 and its 200-day simple moving average is $9.53. Bavarian Nordic A/S has a one year low of $6.86 and a one year high of $14.60.

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) last released its quarterly earnings results on Wednesday, March 5th. The company reported $0.47 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.07. Bavarian Nordic A/S had a net margin of 18.33% and a return on equity of 10.65%. The company had revenue of $299.48 million for the quarter, compared to analyst estimates of $264.06 million. As a group, equities research analysts expect that Bavarian Nordic A/S will post 0.67 EPS for the current year.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.